ALZ-201
Alzheimer's Disease
PreclinicalActive
Key Facts
About Alzinova
Alzinova is a clinical-stage biotech focused on developing disease-modifying immunotherapies for Alzheimer's disease, one of the world's largest unmet medical needs. Its core differentiator is the AβCC Peptide™ platform, designed to precisely target toxic amyloid-beta oligomers, believed to be the primary drivers of neurodegeneration. The company has progressed its lead vaccine candidate, ALZ-101, into Phase 1b clinical trials and is publicly listed on Nasdaq First North Growth Market in Stockholm to fund its ambitious R&D. Alzinova's strategy hinges on validating its oligomer-specific hypothesis to potentially offer a safer and more effective therapeutic option than broader amyloid-targeting approaches.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | Johnson and Johnson Innovative Medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| PMN310 | ProMIS Neurosciences | Phase 1b |